Stryker Corporation has announced a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, a leading peripheral vascular position in the fast-growing segment of venous thromboembolism (VTE), provides mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
The acquisition is expected to expand Stryker's portfolio and provide life-saving solutions to patients who suffer from peripheral vascular diseases. This move is anticipated to accelerate Stryker's impact in endovascular procedures.
The transaction, subject to customary closing conditions, is expected to close by the end of the first quarter of 2025. Further details about the expected impacts to 2025 financial results will be discussed on Stryker’s upcoming fourth-quarter 2024 earnings call scheduled for January 28, 2025.
Inari Medical, Inc. was founded in 2011 and has positively impacted the lives of hundreds of thousands of patients through the development of purpose-built tools that address unmet patient needs. The company provides solutions for VTE clot removal without the use of thrombolytic drugs.
The acquisition of Inari Medical, Inc. by Stryker Corporation signifies the latter's commitment to providing innovative solutions and expanding its footprint in the medical technologies space. As a result of these announcements, the company's shares have moved 22.0% on the market, and are now trading at a price of $79.3. If you want to know more, read the company's complete 8-K report here.
